Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! ; day:2 ; month:12 ; year:2019 ; pages:1-12
BioDrugs ; (2.12.2019), 1-12
- Klassifikation
-
Wirtschaft
- Urheber
-
Dutta, Binita
Huys, Isabelle
Vulto, Arnold G.
Simoens, Steven
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-019-00395-w
- URN
-
urn:nbn:de:101:1-2020032520074108725912
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dutta, Binita
- Huys, Isabelle
- Vulto, Arnold G.
- Simoens, Steven
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Biologics in therapy
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Identifying Program Benefits When Participation Is Misreported
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Adverse reactions to biologics
Biologics in der Dermatologie
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Biologics in therapy
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Identifying Program Benefits When Participation Is Misreported
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Adverse reactions to biologics
Biologics in der Dermatologie
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Biologics in therapy
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Identifying Program Benefits When Participation Is Misreported
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Adverse reactions to biologics
Biologics in der Dermatologie
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar